This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Results From a Multicenter Usage Study

Robert S. Croop, MD; Elizabeth B. Faulkner; Dominic F. Labriola, PhD

Arch Gen Psychiatry. 1997;54(12):1130-1135.

Abstract
Background
Naltrexone hydrochloride is the first medication approved in the United States for the treatment of alcohol dependence in almost 50 years. This study was designed to collect safety data in a setting that reflected the expected clinical use of naltrexone.

Methods
This was a 12-week, nonrandomized, open-label usage study conducted in 40 alcoholism treatment centers throughout the United States, including free-standing alcoholism treatment programs, university clinics, Veterans Administration hospitals, and office-based primary care practices. Eligible patients were assigned, at the investigators' discretion, to a naltrexone treatment group or to a reference group that did not receive study medication. At study entry, patients must have been abstinent from alcohol for 1 to 6 weeks and enrolled in a psychosocial treatment program for alcoholism. Patients often underrepresented in controlled clinical trials, including women and patients with comorbid medical and psychiatric illness, were eligible. Patients with polysubstance abuse or infection with the human immunodeficiency virus were not excluded.

Results
Of 865 patients enrolled, 570 received naltrex-one and 295 were in a reference group. The most common new-onset adverse clinical events in the naltrexone group were nausea (9.8%) and headache (6.6%). Naltrexone was discontinued in 15.0% of patients because of adverse events, most frequently nausea. The results of liver function tests in the naltrexone group were similar to those in the reference group. No deaths occurred during the study.

Conclusions
This is the largest study to date describing the safety of naltrexone in a heterogeneous population of persons with alcoholism. No new safety concerns were identified.

Author Affiliations
for The Naltrexone Usage Study Group

From The DuPont Merck Pharmaceutical Company, Wilmington, Del. Members of the Naltrexone Usage Study Group are listed in the box on page 1133.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Novel {micro}-Opioid Receptor Antagonist, [N-Allyl-Dmt1]Endomorphin-2, Attenuates the Enhancement of GABAergic Neurotransmission by Ethanol
Li et al.
Alcohol Alcohol 2009;44:13-19.
ABSTRACT | FULL TEXT  

Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial
Jayaram-Lindstrom et al.
Am. J. Psychiatry 2008;165:1442-1448.
ABSTRACT | FULL TEXT  

Naltrexone for the Management of Alcohol Dependence
Anton
NEJM 2008;359:715-721.
FULL TEXT  

Injectable, Sustained-Release Naltrexone for the Treatment of Opioid Dependence: A Randomized, Placebo-Controlled Trial
Comer et al.
Arch Gen Psychiatry 2006;63:210-218.
ABSTRACT | FULL TEXT  

Effect of innappropriate naltrexone use in a heroin misuser
Boyce et al.
Emerg. Med. J. 2003;20:381-382.
ABSTRACT | FULL TEXT  

Bridging the Gap: A Hybrid Model to Link Efficacy and Effectiveness Research in Substance Abuse Treatment
Carroll and Rounsaville
Psychiatr. Serv. 2003;54:333-339.
ABSTRACT | FULL TEXT  

Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism: A Double-blind, Placebo-Controlled Study
Kiefer et al.
Arch Gen Psychiatry 2003;60:92-99.
ABSTRACT | FULL TEXT  

Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism
Sinclair
Alcohol Alcohol 2001;36:2-10.
ABSTRACT | FULL TEXT  

A Double-blind, Placebo-Controlled Study of Oral Nalmefene for Alcohol Dependence
Mason et al.
Arch Gen Psychiatry 1999;56:719-724.
ABSTRACT | FULL TEXT  

Drug Therapy for Alcohol Dependence
Swift
NEJM 1999;340:1482-1490.
FULL TEXT  

Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
Garbutt et al.
JAMA 1999;281:1318-1325.
ABSTRACT | FULL TEXT  

Inhibitory pathways and the inhibition of luteinizing hormone-releasing hormone release by alcohol
Lomniczi et al.
Proc. Natl. Acad. Sci. USA 2000;97:2337-2342.
ABSTRACT | FULL TEXT